TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04852978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection
Study: NCT05225415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Orally administered CT1812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Orally administered CT1812

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT1812
Description: Orally administered CT1812
Study: NCT04620538

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
Study: NCT06789328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perineural Dexamethasone 4mg
Description: PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
Study: NCT06159296

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydroxy gas
Description: Hydroxy gas is a combination of hydrogen and oxygen together.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydroxy gas
Description: Hydroxy gas is a combination of hydrogen and oxygen together.
Study: NCT06338644

Intervention type: DRUG
Intervention: Palbociclib
Description: 3 weeks on, 1 week off

Intervention type: DRUG
Intervention: Palbociclib
Description: 3 weeks on, 1 week off
Study: NCT04620538

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
Study: NCT06151938

Intervention type: DRUG
Intervention: Standardised allergen extract from house dust mites
Description: Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
Study: NCT04852978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection
Study: NCT06438224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: Those in the ESWT group were asked to select the most hypertrophic and retracting scars for treatment. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals.
Study: NCT06165874

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-RW102 PET Imaging
Description: Intravenous injection of 1.8 MBq\[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RW102 in a single dose.
Study: NCT05965895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided continuous serratus anterior plane block
Description: Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous dexmedetomidine infusion
Description: Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
Study: NCT06789328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous Dexamethsone 4mg
Description: PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
Study: NCT06789471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium husk
Description: Psyllium husk, derived from the seeds' husks of the Plantago ovata plant, is a plant-based fiber supplement.
Study: NCT06789861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT5
Description: Direct Intravenous administration of TT5 (5 ascending doses in Single Ascending Dose Part and 3 ascending doses administered during 7 days in Multiple Ascending Dose Part in healthy volunteers) Direct Intravenous administration of TT5 in surgical patients (4 doses administered on the same day) in surgical patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - TT5 vehicle
Description: Intravenous administration of vehicule, according to the same drug regimen than TT5
Study: NCT06788561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular Nerve Stimulation
Description: Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: s-taVNS
Description: Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
Study: NCT05809596

Intervention type: DEVICE
Group type: OTHER
Intervention: WATCHMAN FLX Pro LAAC Device
Description: Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
Study: NCT05734066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Administered as intravenous (IV) infusion once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Administered as intravenous (IV) infusion once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
Study: NCT06112171

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravascular lithotripsy
Description: Lesion preparation with Shockwave Medical Peripheral Lithotripsy System

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard lesion preparation
Description: Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
Study: NCT06112925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, \& smoking cessation), drug adherence, and self-monitoring of the diseases.
Study: NCT06438224

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: the sham group was treated using an adapter that had the same shape but did not emit any energy
Study: NCT05948683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: The stimulant MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: The stimulant MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose
Study: NCT06323239

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for metastatic lesions
Study: NCT05041738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral Cryotherapy
Description: small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracanal Cryotherapy
Description: Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
Study: NCT06323239

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose Radiotherapy (LDRT)
Description: LDRT for metastatic lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 6 cycles for combined therapy. Toripalimab maintenance for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 cycles for combined therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT for primary lesion
Study: NCT04927013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based Outreach Intervention for Survivors
Description: The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outreach for Survivors
Description: The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based Outreach Intervention for Close Relatives
Description: Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outreach for Close Relatives
Description: The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
Study: NCT06059885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus tyrosine kinase inhibitor
Description: Lenvatinib, tyrosine kinase inhibitor (TKIs)
Study: NCT05784389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low PRAL
Description: Two weeks on a low PRAL diet compared to 2 week free living
Study: NCT05008328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy plus standard care during an SBT
Description: If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care during an SBT
Description: The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
Study: NCT06118528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blur Obfuscation
Description: Blurring is applied to the RGB images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartoon Obfuscation
Description: Cartoonization is applied to the RGB images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edge Obfuscation
Description: A black background and simple outlines of objects/people are applied to the RGB images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Obfuscation (raw)
Description: No editing is performed on the RGB images.
Study: NCT06642753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immediate implant with buccal plate augmentation using sticky bone
Description: * Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the pouch .

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant with sticky bone as a filling material in the jumping gap
Description: Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the jumping gap.
Study: NCT05548634

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic
Study: NCT05785832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM
Description: The t:slim X2 insulin pump with Control-IQ technology 1.5 is derived from the commercially available t:slim X2 with Control-IQ, with additional features. It will be used with the Dexcom G6 CGM.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy plus continuous glucose monitoring (CGM)
Description: Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
Study: NCT05548634

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic
Study: NCT05809687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DKP21102_C
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKP21102_B
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DKP21102_A
Description: Active Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKP21102_A
Description: Active Control
Study: NCT06633224

Intervention type: PROCEDURE
Intervention: Blood Specimen Collection
Description: Blood samples will be obtained throughout the course of the study

Intervention type: OTHER
Intervention: Stool Specimen Collection
Description: Stool samples will be obtained throughout the course of the study

Intervention type: OTHER
Intervention: Quality of Life (QOL) Questionnaires
Description: Surveys will be given throughout the course of the study.
Study: NCT04151602

Intervention type: BEHAVIORAL
Intervention: Smoked illicit drug use
Description: The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones

Intervention type: BEHAVIORAL
Intervention: Smoked illicit drug use
Description: The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
Study: NCT04924322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
Study: NCT06166277

Intervention type: PROCEDURE
Intervention: Ablation procedure
Description: Cardioneuroablation procedure or permanent pacemaker placement
Study: NCT05502250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, cisplatin and tislelizumab
Description: All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line.